Posted in | News | Medical Sensor

CardioComm HeartCheck ECG Monitor Used to Detect Atrial Fibrillation Screening in Toronto

CardioComm Solutions has announced that the HeartCheck ECG Monitor was used to screen patients for atrial fibrillation at a screening event conducted in Toronto on March 31, 2012. The event was a part of the annual heart symposium conducted by the Heart and Stroke Foundation’s Chinese Canadian Council.

The event, titled "All About a Woman's Heart" witnessed the screening of 1,300 people for detection of atrial fibrillation using electrocardiogram readings. Earlier screening events employed pulse-detection to detect rapid and irregular heartbeat, which is attributed as a risk factor for stroke. The use of the CardioComm ECG monitor will be view the ECG waveform for the conclusive identification of cardiac arrhythmias such as atrial fibrillation.

The Chief Operating Officer of Ontario Heart and Stroke Foundation, Tom McAllister stated that stroke and heart disease is attributed as the number one cause of death in women. McAllister also added that cardiovascular disease claims the life of more Canadian women than all the forms of cancer claim together.

The Chief Executive Officer of CardioComm, Etienne Grima stated that the decision of the Foundation to use the HeartCheck ECG screening tool instead of simple pulse monitoring is vital in helping patients determine if they have any other form of arrhythmia or atrial fibrillation. The wrist-pulse monitoring requires highly trained care providers since differentiating between an irregular and rapid heart rate is very difficult. The ECG signal helps physicians determine the morphology of the recording and provides a clear picture of the heart rate and enables on-the-spot diagnosis of a patient with atrial fibrillation.

The HeartCheck ECG Monitor is a FDA-cleared, portable device that detects arrhythmias in patients at high risk for atrial fibrillation, heart attack, coronary heart disease, high blood pressure, sleep apnea, heart valve disease, congenital heart defects and heart failure. The other HeartCheck solutions offered by CardioComm include the compact HeartCheck Pen Handheld ECG device and the HeartCheck SMART Monitoring.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Choi, Andy. (2019, February 24). CardioComm HeartCheck ECG Monitor Used to Detect Atrial Fibrillation Screening in Toronto. AZoSensors. Retrieved on November 21, 2024 from https://www.azosensors.com/news.aspx?newsID=4027.

  • MLA

    Choi, Andy. "CardioComm HeartCheck ECG Monitor Used to Detect Atrial Fibrillation Screening in Toronto". AZoSensors. 21 November 2024. <https://www.azosensors.com/news.aspx?newsID=4027>.

  • Chicago

    Choi, Andy. "CardioComm HeartCheck ECG Monitor Used to Detect Atrial Fibrillation Screening in Toronto". AZoSensors. https://www.azosensors.com/news.aspx?newsID=4027. (accessed November 21, 2024).

  • Harvard

    Choi, Andy. 2019. CardioComm HeartCheck ECG Monitor Used to Detect Atrial Fibrillation Screening in Toronto. AZoSensors, viewed 21 November 2024, https://www.azosensors.com/news.aspx?newsID=4027.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.